Peringatan Keamanan

Toxicity information regarding anacaulase is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as pain and coagulation abnormalities. Symptomatic and supportive measures are recommended. The carcinogenic effects of anacaulase have not been evaluated, and fertility studies have not been performed. A bacterial reverse mutation assay and an in vitro mammalian chromosome aberration assay showed that anacaulase was not genotoxic.L44717

Anacaulase

DB17449

biotech approved investigational

Deskripsi

Anacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (Ananas comosus L. Merr.). It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides and the N-linked glycan of stem bromelain and small molecule metabolites.L44717 Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns. Removing eschar (a process also known as debridement) through surgical procedures can lead to significant trauma, major blood and heat loss and adjacent tissue damage. They also require specialized surgical personnel and facilities, and autologous skin grafting may be needed. Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.A256047,A256052,A256057 The EMA approved the use of anacaulase in 2013,A256047,A256052 and in January 2023, anacaulase received FDA approval.L44717

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean elimination half-life of anacaulase ranges from 12 to 17 hours, and there is a low presence of this product in serum 72 hours after treatment.[L44722]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Anacaulase that is applied topically to deep partial and full thickness burn wounds is rapidly absorbed, with a Tmax of 4 hours. After 72 hours, most patients had no quantifiable concentrations of this product. The AUC of bromelain, a component of anacaulase, is correlated with the anacaulase dose and the size of the treated area, but not the depth of the burn wound. The Cmax values of anacaulase after the first and second application (17 hours later) are similar. A low level of accumulation (< 2-fold difference) was detected by comparing the AUC0-4 and AUC0-4 dose?normalized levels of the second application with those of the first application.L44717

Metabolisme

As a mixture of proteolytic enzymes, anacaulase is expected to be metabolized by proteases throughout the body.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

Alpha-1-antichymotrypsin SERPINA3
Alpha-2-macroglobulin A2M

Referensi & Sumber

Synthesis reference: Rosenberg, L., et al. (2013). Proteolytic extract from bromelain for the treatment of connective tissue disorders (WIPO Patent No. WO 2013/011514 A1). World Intellectual Property Organization. https://patentimages.storage.googleapis.com/b2/1e/1b/400a744ebc007f/WO2013011514A1.pdf
Artikel (PubMed)
  • PMID: 36193282
    Serracanta J, Baena J, Martinez-Mendez JR, Sanchez-Sanchez M, Lopez-Suso E, Galeiras R, Perez-Del-Caz MD, Vivo-Benlloch C, Monclus-Fuertes E, Casalduero-Viu J, Martin-Playa P, Ugalde-Gutierrez M, Gacto-Sanchez P, Rincon-Ferrari MD, Piqueras-Perez JM, Martin-Luengo A: Bromelain-based enzymatic burn debridement: Spanish multidisciplinary consensus. Eur J Plast Surg. 2022 Sep 29:1-9. doi: 10.1007/s00238-022-01999-2.
  • PMID: 32241591
    Hirche C, Kreken Almeland S, Dheansa B, Fuchs P, Governa M, Hoeksema H, Korzeniowski T, Lumenta DB, Marinescu S, Martinez-Mendez JR, Plock JA, Sander F, Ziegler B, Kneser U: Eschar removal by bromelain based enzymatic debridement (Nexobrid(R)) in burns: European consensus guidelines update. Burns. 2020 Jun;46(4):782-796. doi: 10.1016/j.burns.2020.03.002. Epub 2020 Mar 30.
  • PMID: 24074719
    Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ: A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014 May;40(3):466-74. doi: 10.1016/j.burns.2013.08.013. Epub 2013 Sep 26.

Contoh Produk & Brand

Produk: 2 • International brands: 1
Produk
  • Nexobrid
    Kit • 158 mg/1g • Topical • US • Approved
  • Nexobrid
    Kit • 158 mg/1g • Topical • US • Approved
International Brands
  • NexoBrid — MediWound LTD

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul